

WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of 748 SEQ ID NO: 1-45,196, 752 SEQ ID NO: 1-13,192, 778 SEQ ID NO: 1-94, 779 SEQ ID NO: 1-128, 782 SEQ ID NO: 1-10,451, 784 SEQ ID NO: 1-10,289, 785 SEQ ID NO: 1-3796, 787 SEQ ID NO: 1-3960, 788 SEQ ID NO: 1-14,074, 789 SEQ ID NO: 1-6391, 790 SEQ ID NO: 1-30,533, 791 SEQ ID NO: 1-5822, and 792 SEQ ID NO: 1-8502, a mature protein coding portion of 748 SEQ ID NO: 1-45,196, 752 SEQ ID NO: 1-13,192, 778 SEQ ID NO: 1-94, 779 SEQ ID NO: 1-128, 782 SEQ ID NO: 1-10,451, 784 SEQ ID NO: 1-10,289, 785 SEQ ID NO: 1-3796, 787 SEQ ID NO: 1-3960, 788 SEQ ID NO: 1-14,074, 789 SEQ ID NO: 1-6391, 790 SEQ ID NO: 1-30,533, 791 SEQ ID NO: 1-5822, and 792 SEQ ID NO: 1-8502, an active domain of 748 SEQ ID NO: 1-45,196, 752 SEQ ID NO: 1-13,192, 778 SEQ ID NO: 1-94, 779 SEQ ID NO: 1-128, 782 SEQ ID NO: 1-10,451, 784 SEQ ID NO: 1-10,289, 785 SEQ ID NO: 1-3796, 787 SEQ ID NO: 1-3960, 788 SEQ ID NO: 1-14,074, 789 SEQ ID NO: 1-6391, 790 SEQ ID NO: 1-30,533, 791 SEQ ID NO: 1-5822, and 792 SEQ ID NO: 1-8502, and complementary sequences thereof.
2. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide hybridizes to the polynucleotide of claim 1 under stringent hybridization conditions.
3. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide has greater than about 90% sequence identity with the polynucleotide of claim 1.
4. The polynucleotide of claim 1 wherein said polynucleotide is DNA.
5. An isolated polynucleotide of claim 1 wherein said polynucleotide comprises the complementary sequences.

6. A vector comprising the polynucleotide of claim 1.
7. An expression vector comprising the polynucleotide of claim 1.
8. A host cell genetically engineered to comprise the polynucleotide of claim 1.
9. A host cell genetically engineered to comprise the polynucleotide of claim 1 operatively associated with a regulatory sequence that modulates expression of the polynucleotide in the host cell.
10. An isolated polypeptide, wherein the polypeptide is selected from the group consisting of:
 - (a) a polypeptide encoded by any one of the polynucleotides of claim 1; and
 - (b) a polypeptide encoded by a polynucleotide hybridizing under stringent conditions with any one of 748 SEQ ID NO: 1-45,196, 752 SEQ ID NO: 1-13,192, 778 SEQ ID NO: 1-94, 779 SEQ ID NO: 1-128, 782 SEQ ID NO: 1-10,451, 784 SEQ ID NO: 1-10,289, 785 SEQ ID NO: 1-3796, 787 SEQ ID NO: 1-3960, 788 SEQ ID NO: 1-14,074, 789 SEQ ID NO: 1-6391, 790 SEQ ID NO: 1-30,533, 791 SEQ ID NO: 1-5822, or 792 SEQ ID NO: 1-8502.
11. A composition comprising the polypeptide of claim 10 and a carrier.
12. An antibody directed against the polypeptide of claim 10.
13. A method for detecting the polynucleotide of claim 1 in a sample, comprising:
 - a) contacting the sample with a compound that binds to and forms a complex with the polynucleotide of claim 1 for a period sufficient to form the complex; and

b) detecting the complex, so that if a complex is detected, the polynucleotide of claim 1 is detected.

14. A method for detecting the polynucleotide of claim 1 in a sample, comprising:

- a) contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the polynucleotide of claim 1 under such conditions;
- b) amplifying a product comprising at least a portion of the polynucleotide of claim 1; and
- c) detecting said product and thereby the polynucleotide of claim 1 in the sample.

15. The method of claim 14, wherein the polynucleotide is an RNA molecule and the method further comprises reverse transcribing an annealed RNA molecule into a cDNA polynucleotide.

16. A method for detecting the polypeptide of claim 10 in a sample, comprising:

- a) contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex; and
- b) detecting formation of the complex, so that if a complex formation is detected, the polypeptide of claim 10 is detected.

17. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:

- a) contacting the compound with the polypeptide of claim 10 under conditions sufficient to form a polypeptide/compound complex; and
- b) detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

18. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:

- a) contacting the compound with the polypeptide of claim 10, in a cell, under conditions sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and
- b) detecting the complex by detecting reporter gene sequence expression, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

19. A method of producing the polypeptide of claim 10, comprising,

- a) culturing a host cell comprising a polynucleotide sequence selected from the group consisting of a polynucleotide sequence of 748 SEQ ID NO: 1-45,196, 752 SEQ ID NO: 1-13,192, 778 SEQ ID NO: 1-94, 779 SEQ ID NO: 1-128, 782 SEQ ID NO: 1-10,451, 784 SEQ ID NO: 1-10,289, 785 SEQ ID NO: 1-3796, 787 SEQ ID NO: 1-3960, 788 SEQ ID NO: 1-14,074, 789 SEQ ID NO: 1-6391, 790 SEQ ID NO: 1-30,533, 791 SEQ ID NO: 1-5822, and 792 SEQ ID NO: 1-8502, a mature protein coding portion of SEQ ID NO: 1-739, an active domain of 748 SEQ ID NO: 1-45,196, 752 SEQ ID NO: 1-13,192, 778 SEQ ID NO: 1-94, 779 SEQ ID NO: 1-128, 782 SEQ ID NO: 1-10,451, 784 SEQ ID NO: 1-10,289, 785 SEQ ID NO: 1-3796, 787 SEQ ID NO: 1-3960, 788 SEQ ID NO: 1-14,074, 789 SEQ ID NO: 1-6391, 790 SEQ ID NO: 1-30,533, 791 SEQ ID NO: 1-5822, and 792 SEQ ID NO: 1-8502, complementary sequences thereof and a polynucleotide sequence hybridizing under stringent conditions to 748 SEQ ID NO: 1-45,196, 752 SEQ ID NO: 1-13,192, 778 SEQ ID NO: 1-94, 779 SEQ ID NO: 1-128, 782 SEQ ID NO: 1-10,451, 784 SEQ ID NO: 1-10,289, 785 SEQ ID NO: 1-3796, 787 SEQ ID NO: 1-3960, 788 SEQ ID NO: 1-14,074, 789 SEQ ID NO: 1-6391, 790 SEQ ID NO: 1-30,533, 791 SEQ ID NO: 1-5822, and 792 SEQ ID NO: 1-8502, under conditions sufficient to express the polypeptide in said cell; and
- b) isolating the polypeptide from the cell culture or cells of step (a).

20. An isolated polypeptide encoded by a polynucleotide sequence selected from the group consisting of 748 SEQ ID NO: 1-45,196, 752 SEQ ID NO:

1-13,192, 778 SEQ ID NO: 1-94, 779 SEQ ID NO: 1-128, 782 SEQ ID NO: 1-10,451, 784 SEQ ID NO: 1-10,289, 785 SEQ ID NO: 1-3796, 787 SEQ ID NO: 1-3960, 788 SEQ ID NO: 1-14,074, 789 SEQ ID NO: 1-6391, 790 SEQ ID NO: 1-30,533, 791 SEQ ID NO: 1-5822, and 792 SEQ ID NO: 1-8502, the mature protein portion thereof, the active domain thereof, and complementary sequences thereof.

21. The polypeptide of claim 20 wherein the polypeptide is provided on a polypeptide array.
22. A collection of polynucleotides, wherein the collection comprises the sequence information of at least one of 748 SEQ ID NO: 1-45,196, 752 SEQ ID NO: 1-13,192, 778 SEQ ID NO: 1-94, 779 SEQ ID NO: 1-128, 782 SEQ ID NO: 1-10,451, 784 SEQ ID NO: 1-10,289, 785 SEQ ID NO: 1-3796, 787 SEQ ID NO: 1-3960, 788 SEQ ID NO: 1-14,074, 789 SEQ ID NO: 1-6391, 790 SEQ ID NO: 1-30,533, 791 SEQ ID NO: 1-5822, and 792 SEQ ID NO: 1-8502.
23. The collection of claim 22, wherein the collection is provided on a nucleic acid array.
24. The collection of claim 23, wherein the array detects full-matches to any one of the polynucleotides in the collection.
25. The collection of claim 23, wherein the array detects mismatches to any one of the polynucleotides in the collection.
26. The collection of claim 22, wherein the collection is provided in a computer-readable format.

27. A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising a polypeptide of claim 10 or 20 and a pharmaceutically acceptable carrier.
28. A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising an antibody that specifically binds to a polypeptide of claim 10 or 20 and a pharmaceutically acceptable carrier.